Latest Headlines

  1. Waters Acquires MOBILion Systems, Bringing Advanced Ion-Mobility Separation To Its Mass Spectrometry Portfolio With The Speed And Resolution AI Workflows Require For Proteomics Biomarker Discovery 11/3/2026

    Waters Corporation (NYSE: WAT), a global life sciences and diagnostics leader, today announced that it has acquired MOBILion Systems, Inc., the pioneer of SLIM high-resolution ion mobility separation technology for complex molecular analysis.

  2. Endeavor Health, GoPath Researchers Develop New Genetic Risk Test For Aggressive Prostate Cancer 11/2/2026

    Researchers at Endeavor Health and GoPath Diagnostics have developed a new genetic test that can help predict which men with prostate cancer are most likely to develop aggressive, life-threatening forms of the disease.

  3. AI System May Help Clinical Labs Spot Problems Before They Affect Patients 11/2/2026

    Weill Cornell Medicine researchers have designed an AI system that could help clinical laboratories identify problems before they disrupt testing and delay patient care.

  4. IntelliGenome And NL Diagnóstica Partner To Advance Tuberculosis Detection In Brazil 11/2/2026

    IntelliGenome, Inc., a developer of CRISPR-based molecular diagnostic technologies, today announced an exclusive distribution agreement with NL Diagnóstica to advance its CRISPR-Dx™ diagnostic platform in Brazil.

  5. Roche Receives FDA 510(k) Clearance For New Cobas® Eplex Respiratory Pathogen Panel 3, Enabling Labs To Customize Respiratory Testing For Local Patient Needs 11/2/2026

    Roche announced today the U.S. Food and Drug Administration (FDA) 510(k) clearance of the cobas® eplex respiratory pathogen panel 3 (RP3). Designed for the automated cobas® eplex system, this flexible syndromic test offers up to five customizable panel configurations, enabling labs and clinicians to rapidly and accurately identify the cause of respiratory infections to help ensure timely and effective patient care.

  6. Allarity Therapeutics Secures First Commercial Agreement Under New CLIA Laboratory Services Strategy, Establishing Potential Path To Additional Recurring Revenue 10/30/2026

    Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT pathway inhibitor today announced its first revenue-generating contract under its newly established CLIA-certified laboratory services strategy.

  7. Element Biosciences Launches AVITI Dx™, Bringing CE-Marked IVD Sequencing To Ten EU Countries 10/29/2026

    Element Biosciences, Inc. today announced the commercial launch of AVITI Dx, the company's first CE-marked in vitro diagnostic (IVD) sequencing platform under the European Union's In Vitro Diagnostic Regulation (EU IVDR).

  8. Resonant Clinical Solutions Introduces Suite Of Asset Management Programs To Inform And Support Sample Storage Strategies For Clinical Trials 10/29/2026

    Resonant Clinical Solutions ("Resonant"), a global clinical solutions partner serving life sciences organizations across the clinical supply chain and sample lifecycle, today announced the launch of a suite of programs designed to meet the full range of biorepository asset management needs of life sciences companies.

  9. Haier Biomedical Brings Blood Management And Pharmaceutical Cold Storage Expertise To AABB And ISPE 2026 10/29/2026

    Haier Biomedical (SHA: 688139) showcased blood management and pharmaceutical cold storage solutions at the 2026 AABB Annual Meeting in Atlanta from October 17-19 and the 2026 ISPE Annual Meeting & Expo in the Gaylord National Resort & Convention Center from October 19-20.

  10. Transforming Data Into Actionable Insights In The Lab 10/29/2026

    QuidelOrtho Corporation (Nasdaq: QDEL), a leading global provider of diagnostic solutions, has released episode 62 of its Science Bytes podcast, exploring best practices in AI and informatics to make lab operations smoother.